{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Membrane Transporter & Ion Channel > ElacridarCAS：143664-11-3
Molecular Formula：C34H33N3O5
Molecular Weight：563.64
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：Light yellow to yellow Solid
Qty：
Size：
| CAS | 143664-11-3 |
| Name | Elacridar |
| Molecular Formula | C34H33N3O5 |
| Molecular Weight | 563.64 |
| Solubility | Soluble in DMSO |
| Purity | ≥98% |
| Appearance | Light yellow to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 1532714-185-1 |
| MDL | MFCD00912604 |
| SMILES | O=C1C2=CC=CC(C(NC(C=C3)=CC=C3CCN4CC(C=C(C(OC)=C5)OC)=C5CC4)=O)=C2NC6=C1C=CC=C6OC |
| InChIKey | OSFCMRGOZNQUSW-UHFFFAOYSA-N |
| InChI | InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38) |
| PubChem CID | 119373 |
| Target Point | P-gp(P-glycoprotein);BCRP |
| Passage | Membrane Transporter&Ion Channel |
| Background | It is a potent inhibitor of P-glycoprotein and BCRP. |
| Biological Activity | Elacridar 是一种有效的P-glycoprotein和 BCRP 的抑制剂[1]。 |
| Data Literature Source | [1]. Tang SC，et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94 [2]. Hyafil F，et al. In vitro and in vivo reversal of multidrug resistance by GF120918，an acridonecarboxamide derivative. Cancer Res. 1993 Oct 1;53(19):4595-602. [3]. Sato H，et al. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. Eur J Pharmacol. 2015 Jan 5;746:258-66. [4]. Sane R，et al. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos. 2012 Aug;40(8):1612-9. [5]. de Vries NA，et al. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res. 2007 Nov 1;13(21):6440-9. |
| Unit | Bottle |
| Specification | 5mg 10mg 10mM*1mL in DMSO |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
